Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 486Breast Neoplasms 297Neoplasms 296Colorectal Neoplasms 217Neoplasm Metastasis 190Prostatic Neoplasms 172Ovarian Neoplasms 169Multiple Myeloma 158Lung Neoplasms 157Recurrence 130Melanoma 123Pancreatic Neoplasms 112Squamous Cell Carcinoma of Head and Neck 101Endometrial Neoplasms 100Stomach Neoplasms 99Leukemia, Myeloid, Acute 99Leukemia, Lymphocytic, Chronic, B-Cell 89Small Cell Lung Carcinoma 86Lymphoma, Non-Hodgkin 86Triple Negative Breast Neoplasms 84Carcinoma, Renal Cell 82Carcinoma, Hepatocellular 79Urinary Bladder Neoplasms 76Lymphoma, Large B-Cell, Diffuse 76Lymphoma, Follicular 68Advanced Solid Tumors 65Lymphoma 62Parkinson Disease 4, Autosomal Dominant Lewy Body 60Glioblastoma 58Head and Neck Neoplasms 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Cervical Diseases × 90 days × Clear all
NCT06952660 2026-04-20

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

Pfizer

Phase 4 Recruiting
100 enrolled
Gynecologic

Urogenital Diseases, Uterine Cervical Diseases, Uterine Cervical Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Female, Neoplasms by Site, Uterine Diseases, Uterine Neoplasms, Female Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡